Houston to host inaugural ESPN collegiate esports competition

Game on

ESPN's inaugural esports competition for college students is premiering at Comicpalooza. Jamie McInall/Pexels

For the first time ever, ESPN is hosting the Collegiate Esports Championship, and it's chosen Houston's 11th annual Comicpalooza to host it on May 10 to May 12 at the George R. Brown Convention Center.

"We are honored ESPN has chosen Houston and Comicpalooza for their inaugural Collegiate Esports Championship," says Michael Heckman, Comicpalooza president and senior vice president at Houston First, in a release. "Each year we strive to provide unique experiences for our different pop culture fandoms. Esports is undoubtedly popular and expanding. Teaming up with ESPN to bring the CEC here allows us to engage our audiences in a completely new, exciting way."

Students from hundreds of schools have competed to make it to the semifinals and championship in Houston, and scholarships are on the line. The weekend will have 22 teams across five video games — Hearthstone, Heroes of the Storm, Overwatch, StarCraft II, and Street Fighter V — according to ESPN.

"As universities continue to grow their esports programs at the varsity, non-varsity and club levels, we're proud to be providing a platform for national exposure and recognition of some of the most talented players in the collegiate space," says John Lasker, vice president of Digital Media Programming for ESPN, in a release. "Through our collaboration with top publishers in the industry, players will be able to showcase their talent in high-level competition on some of the most prominent esports titles."

Attendees and fans have access to the events with a Comicpalooza pass, but can also opt for the conference's Gaming Speed Pass for extra perks like reserved seating, a private lounge, and opportunities to meet the talent. Conference goers can also compete themselves in several different video games, according to the website.

Houston is a growing hub for esports. Mainline, a spin off company of Houston-based sports marketing company FanReact, launched this year to account for the growing presence of esports. Mainline's CEO, Chris Buckner, tells InnovationMap in an interview earlier this year that, especially because of this ESPN competition, other cities have their eyes on Houston for esports.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says in an interview. "It's actually a really exciting time for esports in Houston."

Chris Buckner (left), who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Photos courtesy

Houston startup spins off services to focus on esports and hires new CEO

CEO subs in

Houston-based FanReact LLC has decided to divide and conquer. The sports marketing and digital solutions platform announced it will spin off its Mainline business as its own company so that it can better focus on the esports market.

Chris Buckner, who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Both companies are evaluating which assets and employees go where, but both entities plan to hire.

"We see a tremendous opportunity for Mainline in the esports market," says Buckner in a release. "The acceleration in growth in our media and collegiate partnerships gave us the opportunity to focus exclusively on that market. At this point it makes sense to separate our Mainline business from FanReact to give each organization dedicated resources to serve our customers and partners."

Schneidau has has a long career in Houston's tech scene. He spent 12 years at Houston software company PROS and was on the leadership team when the company went public in 2007. Since he left his position as CMO at PROS, he served as the chair of the Talent Committee for Houston Exponential and serves on the board for InnovationMap.

Together, Schneidau and Buckner see the potential for Houston to rise as an epicenter for esports.

"Houston has the second highest viewership of any city in the United States behind Los Angeles," Buckner tells InnovationMap. "I think that's a product of Houston's diversity."

The spinoff allows for Buckner to focus on Mainline, which has become necessary as the business grew over time.

"The Mainline business has been so successful in recent history, that it just made sense for us to dedicate resources toward building that market," Schneidau says. "The momentum in that market as a whole — and in Mainline specifically — is just too large to ignore and not put 100 percent of Chris' time in."

Houston makes sense for an esports market, and the city is on board. ESPN's inaugural collegiate esports championship will be hosted in Houston from May 10 to 12 at the George R Brown Convention Center during the Comicpalooza weekend — and local organizations are on board with the rise of esports in Houston.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says. It's actually a really exciting time for esports in Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings